Stryker Corp. (NYSE:SYK) expanded the number of seats on its board of directors to nine with the addition of the CEO of Belgian biopharm firm Roch Doliveux.
Kalamazoo, Mich.-based Stryker said Doliveux, UCB’s CEO and executive committee chairman since 2005, is the former CEO of Pierre Fabre Pharmaceuticals and former president of Schering-Plough International.
In return for his service on Stryker’s board, Roch will pull down $115,000 a year and an option to purchase 10,228 shares of stock at $51.82 per share, its June 22 closing price, according to a regulatory filing. Stryker shares were trading at $51.08 in late-day activity.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.